Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winquist

Showing results (171-180 of 234) with videos related to

Pageof 24
Sort By:
Clinical Genitourinary Cancer|May 1, 2026
Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World AnalysisBraden Millan, Sunita Ghosh, Naveen S Basappa, et al.
BMC Cancer|March 22, 2013
Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)--study protocol for a randomized phase II trialAnthony C Nichols, John Yoo, J Alex Hammond, et al.
The Lancet. Oncology|June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialJan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Advances in Radiation Oncology|July 11, 2022
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information SystemEric K Nguyen, Aly Khan A Lalani, Sunita Ghosh, et al.
Cancers|July 29, 2023
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and NeckAnagha Gogate, Bryan Bennett, Zia Poonja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glandsMark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 7, 2025
Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trialSondos Zayed, Pencilla Lang, Nancy Read, et al.
European Urology Focus|February 12, 2018
A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in NonseminomaRicardo Leão, Madhur Nayan, Nahid Punjani, et al.
European Urology|April 6, 2024
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR StudyRobert J Motzer, Toni K Choueiri, Thomas Hutson, et al.
Cell Reports. Medicine|May 16, 2026
Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancerPeter Y F Zeng, Jalna Meens, Amir Hossein Karimi, et al.
Pageof 24

Showing results (171-180 of 234) with videos related to

Sort By:
Pageof 24
Clinical Genitourinary Cancer|May 1, 2026
Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World AnalysisBraden Millan, Sunita Ghosh, Naveen S Basappa, et al.
BMC Cancer|March 22, 2013
Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)--study protocol for a randomized phase II trialAnthony C Nichols, John Yoo, J Alex Hammond, et al.
The Lancet. Oncology|June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialJan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Advances in Radiation Oncology|July 11, 2022
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information SystemEric K Nguyen, Aly Khan A Lalani, Sunita Ghosh, et al.
Cancers|July 29, 2023
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and NeckAnagha Gogate, Bryan Bennett, Zia Poonja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glandsMark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 7, 2025
Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trialSondos Zayed, Pencilla Lang, Nancy Read, et al.
European Urology Focus|February 12, 2018
A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in NonseminomaRicardo Leão, Madhur Nayan, Nahid Punjani, et al.
European Urology|April 6, 2024
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR StudyRobert J Motzer, Toni K Choueiri, Thomas Hutson, et al.
Cell Reports. Medicine|May 16, 2026
Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancerPeter Y F Zeng, Jalna Meens, Amir Hossein Karimi, et al.
Pageof 24